解答人乳头瘤病毒疫苗相关疑问；这是一个关乎科学和时间的问题。
Answering human papillomavirus vaccine concerns; a matter of science and time.
机构信息
The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria 3010, Australia.
出版信息
Infect Agent Cancer. 2013 Jun 12;8(1):22. doi: 10.1186/1750-9378-8-22.
Abstract
Since the introduction of the HPV vaccine, questions have been asked about its efficacy in preventing cancer linked with HPV. Concerns about the HPV vaccine safety profile have also been raised. This paper highlights the rapidly growing body of evidence (including clinical trials and post-marketing surveillance) illustrating both the safety of the HPV vaccine, through a detailed investigation of reported adverse events, and its efficacy in reducing both HPV infections rates and the resulting drop in cervical lesions, which have been demonstrated to be good predictors of cervical cancer risk.
摘要
自从 HPV 疫苗问世以来，人们就对其预防 HPV 相关癌症的功效提出了疑问。人们还对 HPV 疫苗的安全性表示担忧。本文重点介绍了不断增加的证据（包括临床试验和上市后监测），这些证据不仅详细调查了报告的不良事件，还表明 HPV 疫苗的安全性及其在降低 HPV 感染率和由此导致的宫颈癌前病变发生率方面的有效性，这些都被证明是宫颈癌风险的良好预测指标。
相似文献
1
Answering human papillomavirus vaccine concerns; a matter of science and time.
Infect Agent Cancer. 2013 Jun 12;8(1):22. doi: 10.1186/1750-9378-8-22.
2
Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics.
J Clin Pharm Ther. 2011 Feb;36(1):1-9. doi: 10.1111/j.1365-2710.2009.01150.x.
3
Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial.
Cancer Med. 2019 Oct;8(14):6195-6211. doi: 10.1002/cam4.2399. Epub 2019 Jul 15.
4
Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review.
Vaccine. 2018 Aug 28;36(36):5416-5423. doi: 10.1016/j.vaccine.2017.07.113. Epub 2017 Aug 8.
5
Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12-15 years: end-of-study results from a community-randomized study up to 6.5 years.
Hum Vaccin Immunother. 2020 Jun 2;16(6):1392-1403. doi: 10.1080/21645515.2019.1692557. Epub 2019 Dec 12.
6
Human papillomavirus (HPV) vaccines as an option for preventing cervical malignancies: (how) effective and safe?
Curr Pharm Des. 2013;19(8):1466-87.
7
Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs.
Int J Gynecol Cancer. 2019 Oct;29(8):1317-1326. doi: 10.1136/ijgc-2019-000582. Epub 2019 Aug 26.
8
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.
9
Human papillomavirus (HPV) vaccination for the prevention of HPV 16/18 induced cervical cancer and its precursors.
GMS Health Technol Assess. 2009 Mar 11;5:Doc04. doi: 10.3205/hta000066.
10
Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.
Hum Vaccin Immunother. 2014;10(8):2147-62. doi: 10.4161/hv.29532.
引用本文的文献
1
The HPV vaccine: knowledge and attitudes among public health nurses and general practitioners in Northern Norway after introduction of the vaccine in the school-based vaccination programme.
Scand J Prim Health Care. 2017 Dec;35(4):387-395. doi: 10.1080/02813432.2017.1358433. Epub 2017 Sep 21.
2
Annual national direct and indirect cost estimates of the prevention and treatment of cervical cancer in Brazil.
Clinics (Sao Paulo). 2015 Apr;70(4):289-95. doi: 10.6061/clinics/2015(04)12.
本文引用的文献
1
Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data.
BMJ. 2013 Apr 18;346:f2032. doi: 10.1136/bmj.f2032.
2
Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Vaccine. 2012 Nov 20;30 Suppl 5:F88-99. doi: 10.1016/j.vaccine.2012.06.095.
3
A review of clinical trials of human papillomavirus prophylactic vaccines.
Vaccine. 2012 Nov 20;30 Suppl 5(0 5):F123-38. doi: 10.1016/j.vaccine.2012.04.108.
4
Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children.
J Infect Dis. 2012 Oct;206(8):1309-18. doi: 10.1093/infdis/jis489. Epub 2012 Aug 2.
5
Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica.
Cancer Discov. 2011 Oct;1(5):408-19. doi: 10.1158/2159-8290.CD-11-0131. Epub 2011 Sep 9.
6
Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination.
Int J Cancer. 2012 Dec 15;131(12):2832-8. doi: 10.1002/ijc.27586. Epub 2012 Apr 30.
7
Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.
BMJ. 2012 Mar 27;344:e1401. doi: 10.1136/bmj.e1401.
8
Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up.
Hum Vaccin Immunother. 2012 Mar;8(3):390-7. doi: 10.4161/hv.18865. Epub 2012 Feb 13.
9
Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls.
J Adolesc Health. 2012 Jan;50(1):38-46. doi: 10.1016/j.jadohealth.2011.10.009.
10
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lancet Oncol. 2012 Jan;13(1):89-99. doi: 10.1016/S1470-2045(11)70286-8. Epub 2011 Nov 8.
Zotero 插件